Every 10-Q that EVOMMUNE INC (EVMN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EVMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVMN filings page.
Evommune, Inc. is a clinical-stage biotech developing therapies for chronic inflammatory diseases, with lead programs EVO756 and EVO301 in Phase 2 development. In June 2026, a Phase 2b trial of EVO756 in chronic spontaneous urticaria failed its primary endpoint, and development for that indication is being discontinued. EVO756 development continues in atopic dermatitis and migraine, with a Phase 2b AD readout expected in September 2026 and a new global Phase 2b migraine prophylaxis trial underway.
For the quarter ended June 30, 2026, Evommune reported no revenue, research and development expenses of $26,412 thousand and general and administrative expenses of $8,483 thousand, leading to a net loss of $32,246 thousand, compared with $13,565 thousand a year earlier. For the first half of 2026, the net loss was $53,920 thousand versus $28,122 thousand in 2025, reflecting higher clinical and public-company costs and the absence of prior-year license revenue.
Liquidity has strengthened following a February 2026 private placement of 4,494,279 shares at $27.88 per share, providing net proceeds of approximately $117.2 million. As of June 30, 2026, cash, cash equivalents and investments totaled $288.0 million, which management expects will fund operations and capital needs into 2028. The company also highlights evolving legal and compliance risks around its and partners’ use of AI technologies.
Evommune, Inc. reported a larger net loss for the quarter ended March 31, 2026 as it continued investing heavily in its anti-inflammatory pipeline. The company generated no revenue this quarter, compared with $3.0 million of license revenue a year earlier.
Research and development expenses rose to $17.3 million and general and administrative costs to $6.6 million, driving a net loss of $21.7 million, or $0.64 per share. Cash, cash equivalents and investments totaled $307.0 million, helped by a $117.2 million private placement, which management believes can fund operations through 2028.
The company’s lead programs, EVO756 and EVO301, are in Phase 2 development targeting chronic inflammatory diseases, with multiple Phase 2b trials underway or planned over the next several years.
Evommune, Inc. reported its first meaningful collaboration revenue while remaining deeply loss-making as it advances inflammatory disease drug candidates EVO756 and EVO301. For the quarter ended September 30, 2025, license revenue was $10.0 million versus none a year earlier, driven mainly by a $10.0 million Maruho milestone, bringing year-to-date license revenue to $13.0 million compared with $7.0 million in 2024.
Total operating expenses rose to $23.3 million for the quarter and $64.4 million for the first nine months, led by research and development spending of $19.6 million in the quarter as clinical programs progressed. The company posted a quarterly net loss of $12.5 million and a nine‑month net loss of $40.6 million, with an accumulated deficit of $192.8 million.
Evommune strengthened its balance sheet with a $65.3 million Series C preferred financing in June 2025 and, after quarter‑end, a $172.5 million initial public offering in November 2025. As of September 30, 2025, it held $26.8 million in cash and cash equivalents and $49.2 million in short‑term investments, and management expects available capital to fund operations for at least twelve months from the financial statement issuance date.